Company news

Eton Pharmaceuticals, Inc. news in 2022

Eton Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 9, 2022

Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

November 1, 2022

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

October 17, 2022

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution

September 12, 2022

Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 29, 2022

Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 10, 2022

Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

August 1, 2022

Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)

July 17, 2022

Eton Pharmaceuticals Announces Sale of Hospital Products

June 23, 2022

Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

May 11, 2022

Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

May 2, 2022

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

April 10, 2022

Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection

April 10, 2022

Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results

March 15, 2022

Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)

March 13, 2022

Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022

March 7, 2022

Calls in 2022